GenFleet Therapeutics (Shanghai) (HAM:Y3L) Total Operating Expense: €43.60 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:Y3L GenFleet Therapeutics (Shanghai) Inc HAM:Y3L
19 GF Score
Price €2.92
! 3 Warning Signs
View Full Analysis

What is GenFleet Therapeutics (Shanghai) Total Operating Expense?

GenFleet Therapeutics (Shanghai) HAM:Y3L -2.80% 19 Total Operating Expense is €43.60 Mil as of Dec. 2025. GuruFocus rates HAM:Y3L with a GF Score™ of 19/100. The stock has 3 warning signs investors should review.

GenFleet Therapeutics (Shanghai)'s Total Operating Expense for the six months ended in Dec. 2025 was €24.46 Mil. GenFleet Therapeutics (Shanghai)'s Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was €43.60 Mil.

GenFleet Therapeutics (Shanghai) Total Operating Expense Related Terms

GenFleet Therapeutics (Shanghai) Total Operating Expense Historical Data

* Premium members only.

The historical data trend for GenFleet Therapeutics (Shanghai)'s Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GenFleet Therapeutics (Shanghai) Total Operating Expense Chart

GenFleet Therapeutics (Shanghai) Annual Data
Trend Dec23 Dec24 Dec25
Total Operating Expense
43.78 50.28 43.68

GenFleet Therapeutics (Shanghai) Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
Total Operating Expense 0.00 26.09 23.56 19.14 24.46
HAM:Y3L
19GF Score
GenFleet Therapeutics (Shanghai) Inc HAM:Y3L
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GenFleet Therapeutics (Shanghai) Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €43.60 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €43.60 Mil mean?
GenFleet Therapeutics (Shanghai) (HAM:Y3L) has a Total Operating Expense of €43.60 Mil as of Dec. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on GenFleet Therapeutics (Shanghai) and its competitors.
Is GenFleet Therapeutics (Shanghai)'s Total Operating Expense too high?
GenFleet Therapeutics (Shanghai)'s current Total Operating Expense is €43.60 Mil. Overall, GenFleet Therapeutics (Shanghai) has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does GenFleet Therapeutics (Shanghai)'s Total Operating Expense compare to VRTX and REGN?
GenFleet Therapeutics (Shanghai)'s Total Operating Expense of €43.60 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on GenFleet Therapeutics (Shanghai) and its competitors. GenFleet Therapeutics (Shanghai)'s current Total Operating Expense is €43.60 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GenFleet Therapeutics (Shanghai) stock overvalued right now?
GenFleet Therapeutics (Shanghai) (HAM:Y3L) has a current Total Operating Expense of €43.60 Mil. The current Total Operating Expense is €43.60 Mil. GenFleet Therapeutics (Shanghai)'s overall GF Score™ is 19/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For GenFleet Therapeutics (Shanghai) (HAM:Y3L), the current Total Operating Expense is €43.60 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GenFleet Therapeutics (Shanghai) Business Description

Other Exchanges 02595:Hong Kong
Address 1206 Zhangjiang Road, Floors 2nd, 3rd, 4th, and 5th, Building 8, Shanghai Pilot Free Trade Zone, Shanghai, CHN, 201203
GenFleet Therapeutics (Shanghai) Inc Company is a clinical-stage biotechnology company. The Company and its subsidiaries are principally engaged in the research, development and commercialisation of pharmaceutical products. The Group is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment.
19GF Score

Get the complete analysis for HAM:Y3L

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.92
Price